These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

316 related items for PubMed ID: 8568812

  • 1. Development of highly potent inhibitors of Ras farnesyltransferase possessing cellular and in vivo activity.
    Leftheris K, Kline T, Vite GD, Cho YH, Bhide RS, Patel DV, Patel MM, Schmidt RJ, Weller HN, Andahazy ML, Carboni JM, Gullo-Brown JL, Lee FY, Ricca C, Rose WC, Yan N, Barbacid M, Hunt JT, Meyers CA, Seizinger BR, Zahler R, Manne V.
    J Med Chem; 1996 Jan 05; 39(1):224-36. PubMed ID: 8568812
    [Abstract] [Full Text] [Related]

  • 2. Bisubstrate inhibitors of farnesyltransferase: a novel class of specific inhibitors of ras transformed cells.
    Manne V, Yan N, Carboni JM, Tuomari AV, Ricca CS, Brown JG, Andahazy ML, Schmidt RJ, Patel D, Zahler R.
    Oncogene; 1995 May 04; 10(9):1763-79. PubMed ID: 7753553
    [Abstract] [Full Text] [Related]

  • 3. [Anti tumor activity of farnesyl transferase inhibitor].
    Yoshimatsu K, Nagasu T.
    Gan To Kagaku Ryoho; 1997 Jan 04; 24(2):145-55. PubMed ID: 9030225
    [Abstract] [Full Text] [Related]

  • 4. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts.
    Sun J, Qian Y, Hamilton AD, Sebti SM.
    Oncogene; 1998 Mar 04; 16(11):1467-73. PubMed ID: 9525745
    [Abstract] [Full Text] [Related]

  • 5. Design and synthesis of non-peptide Ras CAAX mimetics as potent farnesyltransferase inhibitors.
    Qian Y, Vogt A, Sebti SM, Hamilton AD.
    J Med Chem; 1996 Jan 05; 39(1):217-23. PubMed ID: 8568811
    [Abstract] [Full Text] [Related]

  • 6. Induction of parathyroid hormone-related peptide by the Ras oncogene: role of Ras farnesylation inhibitors as potential therapeutic agents for hypercalcemia of malignancy.
    Aklilu F, Park M, Goltzman D, Rabbani SA.
    Cancer Res; 1997 Oct 15; 57(20):4517-22. PubMed ID: 9377563
    [Abstract] [Full Text] [Related]

  • 7. Potent and selective non-cysteine-containing inhibitors of protein farnesyltransferase.
    Augeri DJ, O'Connor SJ, Janowick D, Szczepankiewicz B, Sullivan G, Larsen J, Kalvin D, Cohen J, Devine E, Zhang H, Cherian S, Saeed B, Ng SC, Rosenberg S.
    J Med Chem; 1998 Oct 22; 41(22):4288-300. PubMed ID: 9784104
    [Abstract] [Full Text] [Related]

  • 8. Potent, cell active, non-thiol tetrapeptide inhibitors of farnesyltransferase.
    Hunt JT, Lee VG, Leftheris K, Seizinger B, Carboni J, Mabus J, Ricca C, Yan N, Manne V.
    J Med Chem; 1996 Jan 19; 39(2):353-8. PubMed ID: 8558502
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. N-Arylalkyl pseudopeptide inhibitors of farnesyltransferase.
    deSolms SJ, Giuliani EA, Graham SL, Koblan KS, Kohl NE, Mosser SD, Oliff AI, Pompliano DL, Rands E, Scholz TH, Wiscount CM, Gibbs JB, Smith RL.
    J Med Chem; 1998 Jul 02; 41(14):2651-6. PubMed ID: 9651171
    [Abstract] [Full Text] [Related]

  • 13. Design and in vivo analysis of potent non-thiol inhibitors of farnesyl protein transferase.
    Anthony NJ, Gomez RP, Schaber MD, Mosser SD, Hamilton KA, O'Neil TJ, Koblan KS, Graham SL, Hartman GD, Shah D, Rands E, Kohl NE, Gibbs JB, Oliff AI.
    J Med Chem; 1999 Aug 26; 42(17):3356-68. PubMed ID: 10464022
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
    Lerner EC, Zhang TT, Knowles DB, Qian Y, Hamilton AD, Sebti SM.
    Oncogene; 1997 Sep 26; 15(11):1283-8. PubMed ID: 9315095
    [Abstract] [Full Text] [Related]

  • 15. 2-substituted piperazines as constrained amino acids. Application to the synthesis of potent, non carboxylic acid inhibitors of farnesyltransferase.
    Williams TM, Ciccarone TM, MacTough SC, Bock RL, Conner MW, Davide JP, Hamilton K, Koblan KS, Kohl NE, Kral AM, Mosser SD, Omer CA, Pompliano DL, Rands E, Schaber MD, Shah D, Wilson FR, Gibbs JB, Graham SL, Hartman GD, Oliff AI, Smith RL.
    J Med Chem; 1996 Mar 29; 39(7):1345-8. PubMed ID: 8691462
    [No Abstract] [Full Text] [Related]

  • 16. Clavaric acid and steroidal analogues as Ras- and FPP-directed inhibitors of human farnesyl-protein transferase.
    Lingham RB, Silverman KC, Jayasuriya H, Kim BM, Amo SE, Wilson FR, Rew DJ, Schaber MD, Bergstrom JD, Koblan KS, Graham SL, Kohl NE, Gibbs JB, Singh SB.
    J Med Chem; 1998 Nov 05; 41(23):4492-501. PubMed ID: 9804689
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.